Annette Bennett Burnett, MD
Internal Medicine · Spartanburg, SCNPI 1861691487
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $722, 2.4 times the $296 reported in 2019.
Across 144 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$387
- Dexcom, Inc.$279
- Amgen$261
- Lilly USA, LLC$168
- Pfizer$155
- Novo Nordisk$143
- plus $833 from 25 others
What the payments were for
- Food & beverage$2,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $387 |
| Dexcom, Inc. | 15 | $279 |
| Amgen | 22 | $261 |
| Lilly USA, LLC | 9 | $168 |
| Pfizer | 10 | $155 |
| Novo Nordisk | 10 | $143 |
| Astellas Pharma US Inc | 9 | $133 |
| AstraZeneca | 5 | $83 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $52 |
| Novartis | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Abbott | 2 | $35 |
| Bayer | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Boehringer Ingelheim | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Inari Medical, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Nuwellis, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,227 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $169,266 |
| EliquisApixaban | 105 | $102,771 |
| JardianceEmpagliflozin | 60 | $57,932 |
| MounjaroTirzepatide | 52 | $52,225 |
| JanuviaSitagliptin Phosphate | 48 | $39,582 |
| XareltoRivaroxaban | 27 | $32,092 |
| RybelsusSemaglutide | 15 | $15,782 |
| MyrbetriqMirabegron | 11 | $14,347 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,747 |
| TrulicityDulaglutide | 12 | $11,797 |
| FarxigaDapagliflozin Propanediol | 15 | $10,473 |
| Celecoxib | 106 | $7,319 |
| Potassium Chloride | 285 | $6,576 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $5,577 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $5,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $143 | $185,048156 claims |
| PfizerEliquis | $155 | $102,771105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $168 | $64,02264 claims |
| Boehringer IngelheimJardiance | $27 | $57,93260 claims |
| MerckJanuvia, Janumet Xr | $21 | $45,15861 claims |
| Astellas Pharma US IncMyrbetriq | $133 | $14,34711 claims |
| GSKBreo Ellipta | $14 | $12,74726 claims |
| AstraZenecaFarxiga | $83 | $10,47315 claims |
| AbbVieSynthroid | $387 | $4,35674 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Spartanburg
- Suzanne KovacsSpartanburg$14K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.